Illumina Ventures and Mérieux Equity Partners led a $15m Series A round in Broken String Biosciences.

Illumina Ventures, an independently-managed, healthcare-focused venture firm, and Mérieux Equity Partners, a venture capital and growth equity investments company, led a $15m Series A round in Broken String Biosciences, a genomics company, with participation from HERAN Partners, Tencent and Dieter von Holtzbrinck Ventures. “The gene therapy market, and the essential off-target assessment technology alongside it, is a rapidly growing opportunity. Broken String Biosciences’ team has the technical expertise and resources, paired with its strong connection with a world-leading genomics research institute, to drive this platform forward and transform the way gene editing programs are designed and developed,” Yoann Bonnamour, Mérieux Equity Partners Investment Manager.